Lactate Tags the NLRP3 Inflammasome to Amplify Macrophage Inflammation and Sepsis Damage
Tsinghua researchers find glycolysis-derived lactate chemically modifies NLRP3, switching on inflammatory cell death in macrophages and worsening sepsis in mice.
Summary
When immune cells called macrophages fight bacteria, they shift their metabolism toward aerobic glycolysis, producing lactate. This study shows lactate does more than fuel the cell: it directly modifies the inflammasome sensor protein NLRP3 through a process called lactylation. The enzyme AARS2 attaches the lactyl groups, and mass spectrometry identified two key sites, K24 and K565. Lactylation at these sites helps the adaptor protein ASC assemble onto NLRP3, forming the active inflammasome and triggering pyroptosis, an inflammatory form of cell death. In a mouse model of polymicrobial sepsis, blocking lactate production reduced inflammatory responses. The work links cellular metabolism to innate immunity and points to lactate-driven NLRP3 lactylation as a possible target for inflammatory disease, though it remains preclinical.
Detailed Summary
Chronic, low-grade inflammation is a recognized driver of aging and age-related disease, and the NLRP3 inflammasome is one of its central engines. Understanding what switches NLRP3 on, especially metabolic signals, could open new routes to calm harmful inflammation without broadly suppressing immunity.
Researchers at Tsinghua University studied how metabolic reprogramming in bacteria-infected macrophages shapes pyroptosis, an inflammatory cell death that releases cytokines. They focused on lactate, the end product of aerobic glycolysis, and asked whether it acts as a signaling molecule rather than just a metabolic byproduct.
The team found that endogenous lactate promotes NLRP3 inflammasome activation. It helps recruit the adaptor ASC to NLRP3 assemblies on organelle membranes, enabling the full complex to form. Mechanistically, NLRP3 itself is lactylated, a modification catalyzed by AARS2. LC-MS/MS analysis mapped lactylation to specific lysines, and lactylation at K24 and K565 was shown to enhance inflammasome activation in macrophages. In mice with polymicrobial sepsis, inhibiting lactate production dampened inflammatory responses.
The findings add a direct chemical link between glycolytic metabolism and innate immune signaling. They suggest that targeting lactate production, AARS2, or the NLRP3 lactylation sites could temper excessive inflammasome activity in sepsis and potentially other NLRP3-driven conditions.
Caveats: only the abstract was available, so details on models, effect sizes, and inhibitor specificity are unknown. The work is preclinical, using cell and mouse systems. Lactate has many roles, so systemic lactate suppression could carry trade-offs, and relevance to human disease or aging remains to be tested.
Key Findings
- Lactate from aerobic glycolysis promotes NLRP3 inflammasome activation and pyroptosis in macrophages.
- Endogenous lactate helps ASC get recruited to NLRP3 on organelle membranes, enabling inflammasome complex assembly.
- AARS2 was identified as the enzyme that lactylates NLRP3.
- LC-MS/MS confirmed NLRP3 lactylation at K24 and K565, and these sites enhance inflammasome activation.
- Blocking lactate production reduced inflammatory responses in a mouse model of polymicrobial sepsis.
Methodology
The study used macrophage cell models of NLRP3 inflammasome activation and pyroptosis, combined with LC-MS/MS to map lactylation sites on NLRP3. Site-specific roles (K24, K565) were tested functionally, and an in vivo polymicrobial sepsis mouse model assessed the effect of inhibiting lactate production.
Study Limitations
Only the abstract was reviewed, so methodological detail, statistics, and inhibitor specificity could not be assessed. Evidence comes from cells and mice, and translation to humans, including aging-related inflammation, is unproven. Lactate has broad physiological roles, so safety of manipulating it is uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: